Viska.Bio Overview
- Year Founded
-
2021
- Status
-
Private
- Employees
-
7
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$1.85M
- Investors
-
1
Viska.Bio General Information
Description
Developer of a fusion protein therapy designed to propose a unique way to target chronic and infectious diseases through the body's innate immune system. The company's technology naturally induces the rupture and death of targeted, unwanted cells, such as cancer, and trains the body's immune system to protect itself and prevent the recurrence of such cells, enabling patients to undergo cancer therapy easily.
Contact Information
Website
www.viska.bioCorporate Office
- LabCentral
- 700 Main Street
- Cambridge, MA 02139
- United States
Corporate Office
- LabCentral
- 700 Main Street
- Cambridge, MA 02139
- United States
Viska.Bio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Early Stage VC (Series A) | 24-Oct-2022 | $1.85M | Completed | Startup |
Viska.Bio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A-1 | ||||||||
| Series A |
Viska.Bio Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Viska.Bio Patents
Viska.Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025171188-A1 | Modified xanthine oxidase-antibody complexes and methods thereof | Pending | 07-Feb-2024 | ||
| WO-2025155608-A1 | Systems and methods for detection of cancer using fatty acids | Pending | 18-Jan-2024 | ||
| EP-4496810-A1 | Methods and systems for applications involving antigen-presenting cells | Pending | 23-Mar-2022 | ||
| EP-4496810-A4 | Methods and systems for applications involving antigen-presenting cells | Pending | 23-Mar-2022 | ||
| US-20250205355-A1 | Methods and systems for applications involving antigen-presenting cells | Pending | 23-Mar-2022 | A61K47/6815 |
Viska.Bio Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Viska.Bio Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Hammerstone Capital | Family Office | Minority |
Viska.Bio FAQs
-
When was Viska.Bio founded?
Viska.Bio was founded in 2021.
-
Where is Viska.Bio headquartered?
Viska.Bio is headquartered in Cambridge, MA.
-
What is the size of Viska.Bio?
Viska.Bio has 7 total employees.
-
What industry is Viska.Bio in?
Viska.Bio’s primary industry is Drug Discovery.
-
Is Viska.Bio a private or public company?
Viska.Bio is a Private company.
-
What is the current valuation of Viska.Bio?
The current valuation of Viska.Bio is .
-
What is Viska.Bio’s current revenue?
The current revenue for Viska.Bio is .
-
How much funding has Viska.Bio raised over time?
Viska.Bio has raised $1.85M.
-
Who are Viska.Bio’s investors?
Hammerstone Capital has invested in Viska.Bio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
